Imunon Inc. has published a document detailing a Phase I/II study on the safety and efficacy of the investigational product IMNN-001, in combination with standard of care treatment, for patients newly diagnosed with advanced epithelial ovarian cancer. The document provides updated survival analysis from the OVATION-2 trial, highlighting the study's primary and secondary endpoints, including safety, progression-free survival, overall survival, and response rates. The full document can be accessed through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。